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Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic 
manifestations (RVCL-S) is a rare, autosomal dominant condition caused by 
mutations in the TREX1 gene.1,2 Typically, vascular retinopathy becomes apparent in 
the fourth or fifth decade, soon followed by clinical manifestations of progressive 
focal and global brain disease. Brain imaging reveals rim-enhancing mass lesions 
and/or punctate hyperintense white matter lesions with or without nodular 
enhancement, often in combination with focal white matter calcifications. Many 
patients will also have, or develop, liver and kidney dysfunction, anaemia with or 
without gastrointestinal bleeding, hypertension, migraine, and mild Raynaud’s 
phenomenon.2 We describe two brothers with genetically-proven RVCL-S due to a 
mutation in the TREX1 gene (3688_3689insG) encoding the mutant protein V235fs. 
The clinical history, radiology, treatment and outcomes for the two brothers are 
presented as online supplementary data (figure S1).  
 
In Case 1, multiple sclerosis (MS) with tumefactive demyelinating lesions, cerebral 
vasculitis and neoplasm were all considered as diagnostic possibilities until the 
patient’s brother also became symptomatic, indicating a possible genetic cause. The 
father of the two brothers was probably affected but confirmation is no longer 
possible. The consanguineous family history in our cases is unlikely to be significant 
as RVCL-S is an autosomal dominant rather than recessive condition. A recessive 
mutation in TREX1 causes Aicardi-Goutieres syndrome (AGS), which presents in the 
first year of life with acquired microcephaly, developmental delay, encephalopathy, 
spasticity and extrapyramidal signs. Like RVCL-S, AGS is notable for neuropathology 
demonstrating microangiopathy and microinfarction. 
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The MRI features of RVCL-S include periventricular white matter T2 
hyperintensities, calcifications and infarcts.2 Tumefactive lesions are found in 
approximately 50% of cases with a predilection for the frontoparietal lobes.3 When 
accompanied by smaller periventricular lesions these may be mistaken for tumefactive 
demyelination.  
 
As in Case 1, neuropathology in patients with RVCL-S reveals areas of ischaemia and 
necrosis secondary to an occlusive endotheliopathy of small and medium-sized 
arteries (Fig. 1).2 Microvascular endothelial dysfunction also links clinical symptoms 
of Raynaud’s phenomenon, migraine, and subcortical cognitive dysfunction and 
clinical signs of renal impairment, abnormal liver enzymes, gastrointestinal bleeding, 
anaemia and hypertension.2  
 
In some lesional brain biopsies, modest inflammatory lymphocytic infiltrates are also 
seen. It has been proposed that these inflammatory cells are due to breach of the 
blood-brain-barrier in reaction to focal cerebral ischaemia.2 Another interpretation, 
however, would be that there is an inflammatory contribution to lesion pathogenesis. 
Indeed, a link between TREX1 mutations and immunity is now recognised. Certain 
mutations in the TREX1 gene, which encodes the major mammalian 3'-5' DNA 
exonuclease, lead to cytosolic accumulation of nucleic acids that trigger an innate 
immune response by binding to cyclic GMP-AMP synthase (cGAS). This can lead to 
upregulation of type 1 interferon, and downstream autoimmunity similar to that 
induced by viral nucleic acid,4 although it has not been shown whether there is an 
upregulation of type 1 interferon in the plasma of patients with RVCL-S. In humans, 
2-3% of patients with the immune-mediated condition systemic lupus erythematosis 
(SLE) have TREX1 mutations, and heterozygous mutations in TREX1 underlie the 
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autoimmune condition familial chilblain lupus. As in SLE, AGS is associated with 
elevated CSF interferon-alpha and AGS patients may not only have typical lupus 
autoantibodies but also may manifest frank autoimmune disease.5 In Trex1 null mice, 
an inflammatory myocarditis develops that is hypothesised to be due to build-up of 
retroelement complementary DNA.6 Other organs in these mice also demonstrate 
lymphocytic inflammatory infiltrates, although the brain is relatively spared.7  
 
A role for neuroinflammation in lesion pathogenesis might help to explain the marked 
perilesional oedema which accompanies the tumefactive lesions, which is in excess of 
that seen in conventional ischaemic stroke. In addition, neuroinflammation may 
explain the tendency for RVCL-S lesions to relapse and remit as in MS.3 An overlap 
between microvascular ischaemia and neuroinflammation has been proposed in other 
immune-associated CNS conditions such as antiphospholipid syndrome and Susac’s 
syndrome.8 
 
We reported that Case 1 developed lower limb macular rash. Another patient with 
RVCL-S also developed punctate skin lesions on the thighs9 and yet another was 
reported to have skin lesions.10 In the first of these cases, as in our case, pathology 
was consistent with “vasculitis”. Hence, cutaneous manifestations may also form part 
of the broader clinical phenotype of RVCL-S. Further support comes from the 
observation that electron microscopy of a skin biopsy specimen in a patient with 
RVCL-S revealed abnormal multilaminated vascular basement membranes analogous 
to those seen in brain specimens.11  
 
Case 1 improved transiently following corticosteroids when tumefactive lesions 
developed, presumably due to an effect on lesional inflammation and oedema, a 
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phenomenon which has been noted in other cases.11,12 No treatment has been 
described, however, that can arrest or slow progression of RVCL-S.12 As RVCL-S 
mutations are likely to cause a toxic gain-of-function it seems unlikely that candidates 
tested in the Trex1-null mice (loss-of-function) will provide a future therapeutic 
strategy for patients with RVCL-S.4  
 
Although our patient continued to relapse despite treatment with a number of 
immunotherapies, it is conceivable that targeted immune therapies could modify the 
disease course. We are not aware of any cases of RVCL-S treated with the alpha4-
integrin monoclonal antibody inhibitor, natalizumab, but potentially this could reduce 
lymphocyte tracking across the abnormal vascular endothelium in this condition and 
modify CNS lesion formation, as in relapsing-remitting multiple sclerosis.  
 
Vodopivec and colleagues tried the JAK-1 inhibitor, tofacitinib in their RVCL-S 
patient with the rationale of it reducing intracellular interferon alpha, and co-
administered it with maintenance dexamethasone, and hydroxychloroquine, which 
inhibits activation of Toll-like receptors 7 and 9 by exogenous nucleic acid ligands, 
and reduces interferon beta.12 Their patient developed numerous complications before 
the therapy could be adequately trialled, including infections attributed to prolonged 
corticosteroids, but they argue this targeted approach remains a potential therapeutic 
strategy in RVCL-S. 
 
In conclusion, RVCL-S should be suspected in adult patients with unusual cerebral 
and retinal vascular pathology. We suggest that neuroinflammation could play a role 
in brain lesion formation in RVCL-S, the clinical phenotype of RVCL-S be broadened 
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to include skin involvement, and that RVCL-S be considered a rare differential 
diagnosis of tumefactive demyelination. 
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Figure 1  (A) Late phase fluorescein angiogram from Case 1 showing profound retinal ischaemia with capillary dropout, neovascularisation of 
the disc and elsewhere, and vitreous haemorrhage. (B) MRI brain of Case 1 showing fluid attenuated inversion recovery (FLAIR) and (C) post 
gadolinium T1 sequence and (D) diffusion-weighted sequence showing an enhancing tumefactive lesion (pseudotumor) in the right frontal lobe 
with surrounding oedema. Additional smaller periventricular enhancing lesions are also evident in the white matter of the left hemisphere. (E) 
Brain biopsy haematoxylin & eosin stain from Case 1 showing perivascular lymphocytic cuffing (magnification x 600) with inset showing CD3+ 
lymphocytes. (F) Thick walled vessels within an area of brain lesion necrosis (magnification x 400). (G) Brain biopsy from Case 1 showing 
macrophages stained with CD68 with inset showing microglial cells stained for CD163. (H) Skin biopsy haematoxylin & eosin stain from Case 1 
(magnification x600) showing perivascular inflammatory cell infiltrate with leucocytoclasis (fragmented white blood cells) and extravasation of 
red blood vessels. The features are suggestive of a leucocytoclastic vasculitis. (I) MRI brain of Case 2 with axial FLAIR sequence showing a 
pseudotumour in the right frontal lobe with surrounding oedema and midline shift with marked oedema. (J) Brain biopsy haematoxylin & eosin 
stain from Case 2 showing perivascular lymphocytic cuffing (magnification x 600) with inset showing CD3+ lymphocytes. (K) Thick walled 
vessels within an area of brain lesion necrosis (magnification x 400). (G) Brain biopsy from Case 2 showing macrophages stained with CD68 
with inset showing microglial cells stained for CD163.
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CASE REPORTS 
Case 1  
A 35-year-old man presented to his Ophthalmologist in March 2001 complaining of 
floaters in the left eye with reduced vision of 6/36. Examination revealed vitreous 
haemorrhage and retinal ischaemia with areas of non-perfusion and neovascularisation 
confirmed by fluorescein angiography (FA; Fig. 1A). Routine blood tests, serum 
vasculitis screen and CSF protein and cell count were normal. MRI brain revealed small 
foci of T2 hyperintensity in the left frontal lobe with a solitary punctate focus of 
gadolinium enhancement. Neuropsychological testing revealed mild cognitive slowing. 
Single photon emission computed tomography (SPECT) showed a generalized patchy 
pattern of cerebral cortical perfusion. He was diagnosed with a “cerebro-retinal 
vasculitis” and treated empirically with high dose prednisolone followed by intravenous 
(IV) cyclophosphamide monthly for three courses together with pan-retinal laser 
photocoagulation. His vision improved to 6/6 although a nasal hemi-field defect in his 
left eye persisted. 
 
At 12-month follow-up, he complained of headache, deteriorating vision in the left eye 
and had focal left sided neurological signs with increased tone, bradykinesia and 
hyperreflexia in the left upper limb. Cognitively, he was slower and comprehension was 
impaired. CSF showed an elevated protein of 0.65g/L and repeat FA indicated active 
retinal vasculopathy. MRI brain showed a gadolinium-enhancing tumefactive lesion 
(2cm) with surrounding oedema in the right frontal lobe and multiple periventricular 
gadolinium-enhancing lesions bilaterally (Fig. 1B-D).   
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Brain biopsy in April 2002 revealed cerebral white matter necrosis with reactive 
astrocytosis in adjacent brain parenchyma, and perivascular lymphocytic cuffing (Fig. 
1E-G). Some vessels were tortuous with thick hyalinised walls (Fig. 1F). Subsequently, 
he developed six macular lesions on his left calf, and biopsy showed fibrinoid necrosis 
as well as early dermal degenerative changes and ulceration consistent with 
leukocytoclastic vasculitis (Fig. 1H). Follow-up MRI brain showed waxing and waning 
in the size of the white matter lesions.  
 
By mid-2003 acuity in the right eye had worsened due to further retinal ischaemia and 
neovascularisation. In his left eye, acuity was count fingers and there was iris rubeosis 
secondary to retinal ischaemia with increased intraocular pressure. MRI brain in 
December 2003 showed multiple large, confluent periventricular gadolinium-enhancing 
lesions in the deep white matter of the frontal lobes. By February 2004 he required 
hospitalisation because of marked dysphagia with prominent dysarthria, left-sided 
weakness, ataxia and falls. By September 2004 he was confined to a wheelchair and his 
speech was almost unintelligible. Throughout his illness, due to persistent uncertainty 
regarding the diagnosis, including the possibility this might have been an atypical form 
of multiple sclerosis with recurrent tumefactive demyelination, he was variously given 
courses of intravenous and oral corticosteroids, beta-interferon, glatiramer acetate, 
cyclophosphamide and plasmapheresis all of which failed to prevent further relapses. 
He continued to deteriorate and died in January 2008. The course of his worsening 
clinical disability is shown in Fig. S1. 
 
Case 2  
The 41-year-old brother of Case 1 presented in 2004 with a one-week history of 
morning headaches associated with nausea, confusion and drowsiness. MRI revealed a 
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large, deep, right frontal ring-enhancing mass with oedema and mass effect (Fig. 1I). A 
brain tumour was suspected but biopsy of the lesion showed a microvascular 
angiopathic process with coagulative and fibrinoid necrosis within and around the 
lesion and scattered neutrophils, mononuclear cells and histiocytes (Fig. 1J-L). Rare 
degenerate vessels had a hyaline thickened appearance suggesting intimal proliferation 
(Fig 1K).   
  
The only abnormalities on extensive serum testing were elevated serum gamma-
glutamyltransferase of 239 units/L and alkaline phosphatase of 114 units/L. FA showed 
asymptomatic retinal capillary non-perfusion consistent with early retinal disease.  
Follow-up MRI six months later showed new bifrontal white matter hyperintensities 
(anterior corpus callosum and deep white matter of the left frontal lobe).   
 
In view of both brothers’ cerebroretinal pathology, a more detailed family history was 
taken. Their father had died in a nursing home at the age of 65 following a slowly 
progressive, stepwise illness characterised by worsening mobility and cognition which 
commenced in his 50s and was attributed to multiple strokes. Both he and his wife were 
of Calabrian Italian descent and consanguineous in that they were children of identical 
twin brothers. DNA was obtained from Case 1 and 2 and subsequent analysis showed a 
mutation in the TREX1 gene (3688_3689insG) encoding the mutant protein V235fs and 
the diagnosis of RVCL-S was confirmed (see Family 5 in Richard et al. 2017 and Stam 
et al. 2016).
 1,2
 
 
Case 2 was managed conservatively with an emphasis on symptom control and 
rehabilitation between attacks of neurological dysfunction. At the present time, thirteen 
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years since presentation, he is living in a nursing home, visually impaired, bedbound, 
aphasic and prone to status epilepticus (Fig. S1). 
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Supplementary Fig. 1 The clinical disability of the two cases over time as per their 
Modified Rankin Scale (MRS) score. Case 1 is denoted by an X and Case 2 is denoted 
by a ▲. MRS 0 = no symptoms; MRS 1 = no significant disability, able to carry out all 
usual activities, despite some symptoms; MRS 2 = slight disability, able to look after 
own affairs without assistance, but unable to carry out all previous activities; MRS 3 = 
moderate disability, requires some help, but able to walk unassisted; MRS 4 = 
moderately severe disability, unable to attend to own bodily needs without assistance, 
and unable to walk unassisted; MRS 5 = severe disability, requires constant nursing care 
and attention, bedridden, incontinent; MRS 6 = dead.  

